文献速递心境障碍

代谢调控治疗双相抑郁:机制及曲美他嗪的靶向作用

Metabolic regulation to treat bipolar depression: mechanisms and targeting by trimetazidine.
PubMed 文献 · Mol Psychiatry · 2023-06-29

本综述聚焦双相抑郁相关的线粒体功能障碍、炎症和氧化应激等分子机制,并基于基因表达特征筛选已上市药物发现曲美他嗪。临床前与临床文献支持曲美他嗪具有抗炎、抗氧化及在受损时恢复正常线粒体功能的作用,其安全性和耐受性为临床试验治疗双相抑郁提供依据。

要点

  • 双相抑郁与线粒体功能障碍、炎症和氧化应激相关。
  • 曲美他嗪经基因表达特征筛选发现,具抗炎抗氧化及恢复线粒体功能作用。
  • 曲美他嗪安全性耐受性良好,支持开展治疗双相抑郁的临床试验。

核心结论

  • 临床前与临床文献强烈支持曲美他嗪治疗双相抑郁的潜力,其抗炎抗氧化并在线粒体功能受损时恢复正常功能。

研究设计与样本

  • 本综述先梳理双相抑郁相关分子机制,再检索文献评估曲美他嗪对这些改变的作用。
  • 曲美他嗪的发现未设先验假设,采用双相障碍治疗药物组合的基因表达特征并在培养的人神经元样细胞中筛选已上市药物库。

主要发现

  • 双相抑郁的主要分子机制涉及线粒体功能障碍、炎症和氧化应激。
  • 曲美他嗪具有抗炎和抗氧化特性,且仅在线粒体功能受损时使其正常化。

临床怎么用

  • 曲美他嗪已用于治疗心绞痛,具细胞保护和代谢效应(改善葡萄糖利用以产能)。
  • 其已证明的安全性和耐受性为开展治疗双相抑郁的临床试验提供强依据,可能加速其重定位以满足双相抑郁的未满足需求。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Bipolar disorder's core feature is the pathological disturbances in mood, often accompanied by disrupted thinking and behavior. Its complex and heterogeneous etiology implies that a range of inherited and environmental factors are involved. This heterogeneity and poorly understood neurobiology pose significant challenges to existing drug development paradigms, resulting in scarce treatment options, especially for bipolar depression. Therefore, novel approaches are needed to discover new treatment options. In this review, we first highlight the main molecular mechanisms known to be associated with bipolar depression-mitochondrial dysfunction, inflammation and oxidative stress. We then examine the available literature for the effects of trimetazidine in said alterations. Trimetazidine was identified without a priori hypothesis using a gene-expression signature for the effects of a combination of drugs used to treat bipolar disorder and screening a library of off-patent drugs in cultured human neuronal-like cells. Trimetazidine is used to treat angina pectoris for its cytoprotective and metabolic effects (improved glucose utilization for energy production). The preclinical and clinical literature strongly support trimetazidine's potential to treat bipolar depression, having anti-inflammatory and antioxidant properties while normalizing mitochondrial function only when it is compromised. Further, trimetazidine's demonstrated safety and tolerability provide a strong rationale for clinical trials to test its efficacy to treat bipolar depression that could fast-track its repurposing to address such an unmet need as bipolar depression.

来源:Mol Psychiatry,查看原文。版权归原作者所有。

引用

  1. Khanra S, Reddy P, Giménez-Palomo A, et al. Metabolic regulation to treat bipolar depression: mechanisms and targeting by trimetazidine. Mol Psychiatry. 2023. PMID: 37386057. doi:10.1038/s41380-023-02134-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。